CAR-T Long Term Follow Up (LTFU) Study
Conditions
Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Mayo Clinic Arizona, Phoenix, Arizona, United States
City of Hope National Medical Center, Duarte, California, United States
Contact: Principal Investigator (Leslie Popplewell)Childrens Hospital Los Angeles, Los Angeles, California, United States
Contact: Principal Investigator (Alan Wayne)UCLA Medical Center, Los Angeles, California, United States
Contact: Principal Investigator (Aravind Ramakrishnan)UCSF Medical Center, San Francisco, California, United States
Contact: Principal Investigator (Charalambos Andreadis)Stanford University Medical Center, Stanford, California, United States
Contact: Principal Investigator (Kara Davis)Emory University School of Medicine-Winship Cancer Institute, Atlanta, Georgia, United States
Contact: Principal Investigator (Jonathon Cohen)Emory University School of Medicine/Winship Cancer Institute, Atlanta, Georgia, United States
Contact: Study coordinator (Keshawna L. Sherer) · keshawna.sherer@emoryhealthcare.org · 404-778-3708Contact: Principal Investigator (Jonathon Cohen)Childrens Healthcare of Atlanta, Atlanta, Georgia, United States
Contact: Principal Investigator (Muna Qayed)Uni of Chi Medi Ctr Hema and Onco, Chicago, Illinois, United States
Contact: Principal Investigator (Michael R Bishop)University of Chicago Medical Center, Hematology & Oncology, Chicago, Illinois, United States
Contact: Principal Investigator (Michael R. Bishop)University of Kansas Cancer Center SC, Westwood, Kansas, United States
Contact: Principal Investigator (Joseph P McGuirk)University of Kansas Cancer Center, Westwood, Kansas, United States
Contact: Principal Investigator (Joseph P McGuirk)Massachusetts General Hospital, Boston, Massachusetts, United States
Contact: Principal Investigator (Matthew Frigault)Beth Israel Deaconess Med Center, Boston, Massachusetts, United States
Contact: Principal Investigator (Jacalyn Rosenblatt)Dana Farber Cancer Institute, Boston, Massachusetts, United States
Contact: Principal Investigator (Adam Sperling)University of Michigan, Ann Arbor, Michigan, United States
Contact: Principal Investigator (Gregory Yanik)Uni Of Michigan Health System, Ann Arbor, Michigan, United States
Contact: Principal Investigator (John Magenau)University of Michigan Health System SC CTL019, Ann Arbor, Michigan, United States
Contact: Principal Investigator (John Magenau)Wayne State University-Karmanos Cancer Institute, Detroit, Michigan, United States
Contact: Principal Investigator (Abhinav Deol)University of Minnesota, Minneapolis, Minnesota, United States
Children s Mercy Hospital, Kansas City, Missouri, United States
Contact: Principal Investigator (Gary D. Myers)Children's Mercy Hospital SC, Kansas City, Missouri, United States
Contact: Principal Investigator (Gary Myers, MD)Contact: Principal Investigator (Gary D. Myers)Weill Cornell Medical College, New York, New York, United States
Duke Unversity Medical Center SC - CTL019B2205J, Durham, North Carolina, United States
Contact: Principal Investigator (Paul L. Martin)Duke Unversity Medical Center, Durham, North Carolina, United States
Contact: Principal Investigator (Paul L. Martin)Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Contact: Principal Investigator (Stella M. Davies)Cinn Children Hosp Medical Center, Cincinnati, Ohio, United States
Contact: Principal Investigator (Stella M. Davies)Ohio ST Compr Cancer Ctr James Hosp, Columbus, Ohio, United States
Contact: Principal Investigator (David A Bond)Oregon Health & Science University, Portland, Oregon, United States
Contact: Principal Investigator (Brandon Hayes-Lattin)Oregon Health Sciences University, Portland, Oregon, United States
Contact: Principal Investigator (Brandon Hayes-Lattin)The Childrens Hosp of Philadelphia, Philadelphia, Pennsylvania, United States
Contact: Principal Investigator (Stephan Grupp)University of Pennsylvania, Philadelphia, Pennsylvania, United States
Contact: Principal Investigator (Noelle Frey)University of Pennsylvania, Philadelphia, Pennsylvania, United States
Contact: Principal Investigator (Noelle Frey)Thomas Jefferson University, Philadelphia, Pennsylvania, United States
Contact: Principal Investigator (Usama Gergis)Sarah Cannon Research Institute, Nashville, Tennessee, United States
Contact: Principal Investigator (Ian W Flinn)UTSW/Children's Medical Center, Dallas, Texas, United States
Contact: Principal Investigator (Theodore Laetsch, MD)Contact: Principal Investigator (Theodore Laetsch)University of Texas Southwestern Medical Center, Dallas, Texas, United States
Contact: Principal Investigator (Samuel John)MD Anderson Cancer Center SC, Houston, Texas, United States
Contact: Principal Investigator (Jason Westin)MD Anderson Cancer Center, Houston, Texas, United States
Contact: Principal Investigator (Jason Westin)University of Utah Clinical Trials Office, Salt Lake City, Utah, United States
Contact: Principal Investigator (Michael Boyer, MD)Contact: Principal Investigator (Michael Boyer)University of Utah Clinical Trials Office, Salt Lake City, Utah, United States
Contact: Principal Investigator (Michael Pulsipher)University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
Contact: Principal Investigator (Christian Capitini)University of Wisconsin Hospital, Madison, Wisconsin, United States
Contact: Principal Investigator (Christian Capitini)Novartis Investigative Site, Camperdown, New South Wales, Australia
Novartis Investigative Site, Melbourne, Victoria, Australia
Novartis Investigative Site, Melbourne, Victoria, Australia
Novartis Investigative Site, Parkville, Victoria, Australia
Novartis Investigative Site, Murdoch, Western Australia, Australia
Novartis Investigative Site, Herston, Australia
Novartis Investigative Site, Linz, Austria
Novartis Investigative Site, Salzburg, Austria
Novartis Investigative Site, Vienna, Austria
Novartis Investigative Site, Vienna, Austria
Novartis Investigative Site, Ghent, Belgium
Novartis Investigative Site, Hamilton, Ontario, Canada
Novartis Investigative Site, Toronto, Ontario, Canada
Novartis Investigative Site, Montreal, Quebec, Canada
Novartis Investigative Site, Montreal, Quebec, Canada
Novartis Investigative Site, Beijing, China
Novartis Investigative Site, Copenhagen, Denmark
Novartis Investigative Site, Helsinki, Finland
Novartis Investigative Site, Nantes, France
Novartis Investigative Site, Paris, France
Novartis Investigative Site, Paris, France
Novartis Investigative Site, Pierre-Bénite, France
Novartis Investigative Site, Villejuif, France
Novartis Investigative Site, Munich, Bavaria, Germany
Novartis Investigative Site, Regensburg, Bavaria, Germany
Novartis Investigative Site, Würzburg, Bavaria, Germany
Novartis Investigative Site, Frankfurt am Main, Hesse, Germany
Novartis Investigative Site, Cologne, North Rhine-Westphalia, Germany
Novartis Investigative Site, Leipzig, Saxony, Germany
Novartis Investigative Site, Berlin, Germany
Novartis Investigative Site, Hamburg, Germany
Novartis Investigative Site, Ulm, Germany
Novartis Investigative Site, Chaïdári, Greece
Novartis Investigative Site, Hong Kong, Hong Kong
Novartis Investigative Site, Ramat Gan, Israel
Novartis Investigative Site, Tel Aviv, Israel
Novartis Investigative Site, Bologna, BO, Italy
Novartis Investigative Site, Monza, MB, Italy
Novartis Investigative Site, Milan, MI, Italy
Novartis Investigative Site, Milan, MI, Italy
Novartis Investigative Site, Rozzano, MI, Italy
Novartis Investigative Site, Roma, RM, Italy
Novartis Investigative Site, Roma, RM, Italy
Novartis Investigative Site, Fukuoka, Fukuoka, Japan
Novartis Investigative Site, Sapporo, Hokkaido, Japan
Novartis Investigative Site, Sendai, Miyagi, Japan
Novartis Investigative Site, Chuo Ku, Tokyo, Japan
Novartis Investigative Site, Kyoto, Japan
Novartis Investigative Site, Amsterdam, North Holland, Netherlands
Novartis Investigative Site, Utrecht, Netherlands
Novartis Investigative Site, Utrecht, Netherlands
Novartis Investigative Site, Oslo, Norway
Novartis Investigative Site, Oslo, Norway
Novartis Investigative Site, Riyadh, Saudi Arabia
Novartis Investigative Site, Singapore, Singapore
Novartis Investigative Site, Singapore, Singapore
Novartis Investigative Site, Seoul, South Korea
Novartis Investigative Site, Seoul, South Korea
Novartis Investigative Site, Seoul, South Korea
Novartis Investigative Site, Seoul, South Korea
Novartis Investigative Site, Esplugues, Barcelona, Spain
Novartis Investigative Site, L'Hospitalet de Llobregat, Barcelona, Spain
Novartis Investigative Site, Salamanca, Castille and León, Spain
Novartis Investigative Site, Barcelona, Catalonia, Spain
Novartis Investigative Site, Pamplona, Navarre, Spain
Novartis Investigative Site, Barcelona, Spain
Novartis Investigative Site, Madrid, Spain
Novartis Investigative Site, Madrid, Spain
Novartis Investigative Site, Madrid, Spain
Novartis Investigative Site, Seville, Spain
Novartis Investigative Site, Valencia, Spain
Novartis Investigative Site, Taipei, Taiwan
Novartis Investigative Site, Birmingham, United Kingdom
Novartis Investigative Site, London, United Kingdom
Study leads
Novartis Pharmaceuticals
Study Director
Novartis Pharmaceuticals